PFEPfizer

$30.02+30% 1Y

$30.02

$23.1052 weeks$30.42

Is the price fair?

Fair

Neither cheap nor expensive: modest expectations priced in, but at the top of its own P/E range.

1 good, 1 to watch, 1 without data

What the price assumes~+2% a yearderived · Jun 28, 2026

Priced for ~2% a year FCF growth. Little growth is priced in even as revenue fell 7% a year over three years, potential value, or a value trap.

Vs its own P/E rangedearest in 39 quartersderived

Expensive vs its own history: P/E 39.5 vs a 13.7 median over 39 quarters (+189% vs median).

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

P/E (valuation)behind 81% of the market

FCF yieldbetter than 67% of the market

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

Pfizer trades at 39.5× earnings against 40.0× for the median Drug Manufacturers - General name, cheaper than its own group.

39.5

Trailing P/E · Drug Manufacturers - General median 40.0 · cheaper than the typical name in its group

Price / sales: 2.69
Price / sales · today's price, trailing year to Jun 28, 2026
Free cash flow yield: 6.4%
Free cash flow yield · Drug Manufacturers - General median 5.5%
Growth the price implies: +2.3%
Growth the price implies · The price pays for +2.3% free cash flow growth a year for a decade; the business has delivered +0.99% a year over the last three.

Details›

PFE has re-rated away from its own history, so multiplying the old multiple by today's earnings prices a full reversal, not the business
Method	Per share
What its own history would imply	not meaningful, 39.5× today against a 13.7× median
52-week range	$23.10 – $30.42
Today	$30.02

Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.

Today's price against what its own multiples, its cash flow and your growth assumption say it is worth.

Its multiples now against their own history, and how much of the price move came from earnings rather than the multiple.

The closest names by size in the same industry